Dr. Steven A. Greenberg
Site presented by Bill Tillier.
Dr. Stephen Greenberg of Harvard, Cambridge, MA
Inclusion Body Myositis
Greenberg, S. A. (2016). Inclusion Body Myositis. Continuum (Minneapolis, Minn.), 22(6, Muscle and Neuromuscular Junction Disorders), 1871-1888. http://doi.org/10.1212/01.CON.0000511071.58338.1e
Summary: IBM has high unmet medical need. Advances in the mechanistic understanding of IBM as an autoimmune disease will drive effective therapeutic approaches. The identification of a B-cell pathway has resulted in the first identification of an IBM autoantigen and emphasized its status as an autoimmune disease. The recognition that large granular lymphocyte CD8+ T-cell expansions are present in both blood and muscle provides additional biomarkers for IBM and suggests a mechanistic relationship to the neoplastic disease T-cell large granular lymphocytic leukemia.
Cytotoxic T cells go awry in inclusion body myositis
An editorial by Reinhard Hohlfeld
Hohlfeld, R., & Schulze-Koops, H. (2016). Cytotoxic T cells go awry in inclusion body myositis. Brain, 139(5), 1312-1314. http://doi.org/10.1093/brain/aww053
Association of inclusion body myositis with T cell large granular lymphocytic leukaemia
Greenberg, S. A., Pinkus, J. L., Amato, A. A., Kristensen, T., & Dorfman, D. M. (2016). Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain, 139(5), 1348-1360. http://doi.org/10.1093/brain/aww024
ANTI- C N1A ANTIBODIES IN SOUTH AUSTRALIAN PATIENTS WITH INCLUSION BODY MYOSITIS
Limaye, V. S., Lester, S., Blumbergs, P., & Greenberg, S. A. (2016). Anti- C N1A antibodies in South Australian patients with inclusion body myositis. Muscle & Nerve, 53(4), 654-655. http://doi.org/10.1002/mus.24989
The Inclusion Body Myositis Foundation (IBMF)
Steven A. Greenberg, MD, Director